
BIOPHARMACEUTICALS

HALO



LC-MS Analysis of Trastuzumab Using HALO[®] 1000 Å C4

Application Note 151-PR



LC TEST CONDITIONS:

Column: HALO 1000 Å C4, 2.7 µm, 2.1 x 150 mm Part Number: 92712-714 Mobile Phase: A: 10 mM difluoroacetic acid (DFA) in water B: 10 mM difluoroacetic acid in 10/90 water/ acetonitrile Gradient: 32–42% B in 10 min Flow Rate: 0.35 mL/min Pressure: 184 bar Temperature: 80 °C Detection: 280 nm **Injection Volume:** 1.0 µL of 2 mg/mL trastuzumab (glycosylated/deglycosylated) Sample Solvent: 0.1% DFA in 70/30 water/acetonitrile LC System: Shimadzu Nexera

MS TEST CONDITIONS:

MS System: Thermo Fisher Orbitrap VelosPro ETD Scan Time: 6 µscans/250 ms max inject time Scan Range: 1800 to 4000 m/z MS Parameters: Positive ion mode, ESI at +4.0 kV, 225 °C capillary

LC-MS analysis using a HALO 1000 Å C4 Protein column has been used to analyze two samples of the monoclonal antibody, trastuzumab: glycosylated and enzymatically deglycosylated. Minor variant structures are observed in both the glycosylated and deglycosylated monoclonal IgG (small peaks after main peak), indicating that the polypeptides are structure variants.

The glycosylation profile of therapeutic mAbs is an important characteristic, which must be monitored throughout the manufacturing process. Determination of the mass of the deglycosylated IgG confirms the identity and integrity of the protein.

